TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30019283

Group type: EXPERIMENTAL
Intervention: Oncoplastic biopsy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional excisional biopsy
Number of subjects: 80
Study: 27980221

Group type: EXPERIMENTAL
Intervention: Uracil and Tegafur (UFT) maintenance therapy (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity
Number of subjects: 58

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 58
Study: 25916084

Group type: EXPERIMENTAL
Intervention: Daikenchuto (TJ-100)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no TJ-100)
Number of subjects: 45
Study: 23955492

Group type: EXPERIMENTAL
Intervention: Women distressed about low sexual desire
Number of subjects: 2

Group type: COMPARATOR
Intervention: Women not distressed about low sexual desire
Number of subjects: 2
Study: 21404147

Group type: EXPERIMENTAL
Intervention: Alprazolam sublingual tablets (ALP-SL)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Alprazolam conventional tablets (ALP-CT)
Number of subjects: 190
Study: 18353468

Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent implantation, N=25
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cordis coil stent implantation, N=24
Number of subjects: 117

Group type: COMPARATOR
Intervention: Balloon angioplasty, N=42 (23 + 19)
Number of subjects: 117
Study: 17303799

Group type: EXPERIMENTAL
Intervention: vildagliptin (50 mg b.i.d.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 14648339

Group type: EXPERIMENTAL
Intervention: Low-dose enalapril (0.2 mg/kg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose enalapril (0.6 mg/kg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined low-dose enalapril
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined high-dose enalapril
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: End of 20 weeks treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Systolic and diastolic blood pressure
Number of subjects: 25
Study: 11409580

Group type: EXPERIMENTAL
Intervention: amikacin 5 mg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: amikacin 10 mg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: amikacin 15 mg/kg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: isoniazid 6 mg/kg
Number of subjects: 59

Group type: COMPARATOR
Intervention: no drug
Number of subjects: 59
Study: 9744148

Group type: EXPERIMENTAL
Intervention: Dietary advice with cholesterol measurement
Number of subjects: 635

Group type: COMPARATOR
Intervention: No dietary advice but cholesterol measurement
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 635

Group type: COMPARATOR
Intervention: Men
Number of subjects: 635

Group type: COMPARATOR
Intervention: Women
Number of subjects: 635
Study: 7828565

Group type: EXPERIMENTAL
Intervention: Fibrin glue (mean: 5.4 ml)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Polidocanol (mean: 12.1 ml)
Number of subjects: 79
Study: 3237047

Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.10 g NaHCO3·kg‐1 body weight (B)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.15 g NaHCO3·kg‐1 body weight (C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.20 g NaHCO3·kg‐1 body weight (D)
Number of subjects: 9
Study: 31194877

Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 220
Study: 29379001

Group type: COMPARATOR
Intervention: Single Bond Universal (SBU) - uncontaminated (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-1 (cont-1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-2 (cont-2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-3 (cont-3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU) - contamination-4 (cont-4)
Number of subjects: 75

Group type: COMPARATOR
Intervention: All-Bond Universal (ABU) - uncontaminated (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-1 (cont-1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-2 (cont-2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-3 (cont-3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All-Bond Universal (ABU) - contamination-4 (cont-4)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Clearfil S3 Bond Plus (CSBP) - uncontaminated (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-1 (cont-1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-2 (cont-2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-3 (cont-3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond Plus (CSBP) - contamination-4 (cont-4)
Number of subjects: 75
Study: 25406966

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (6000 IU/day for 3 months, then 3000 IU/day for 3 months)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Vitamin D3 supplementation and Placebo
Number of subjects: 87
Study: 23387320

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition treatment
Number of subjects: 324

Group type: COMPARATOR
Intervention: Standard nutrition education
Number of subjects: 324
Study: 22027241

Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 129

Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 129
Study: 18096910

Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (animated GIF)
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (static image)
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (HTML text)
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: e-mail layout with graphics (artwork text)
Number of subjects: 6500

Group type: COMPARATOR
Intervention: courier plain text message
Number of subjects: 6500
Study: 16943584

Group type: EXPERIMENTAL
Intervention: Overt hypothyroidism group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TSH levels higher than 5 microIU/mL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 14600050

Group type: EXPERIMENTAL
Intervention: Network condition
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Random condition
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Teacher condition
Number of subjects: 1961
Study: 10602102

Group type: EXPERIMENTAL
Intervention: Affected eyes in ischemic central retinal vein occlusion (n=18)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Affected eyes in nonischemic central retinal vein occlusion (n=51)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Affected eyes in branch retinal vein occlusion (n=33)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control subjects' eyes
Number of subjects: 102
Study: 9351763

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Successful versions (both groups)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Failed versions (both groups)
Number of subjects: 103
Study: 8416148

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: combinations of autologous blood use with various rHuEPO regimens
Number of subjects: 0
Study: 3621618

Group type: EXPERIMENTAL
Intervention: Dopamine (1 micrograms/kg/min by i.v. infusion)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dopamine (10(‐5) mol/l) in vitro
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dopamine (10(‐9) mol/l‐10(‐5) mol/l) in vitro
Number of subjects: 5
Study: 29408797

Group type: EXPERIMENTAL
Intervention: Cilostazol + Clopidogrel (n=24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clopidogrel alone (n=22)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hematocrit
Number of subjects: 46
Study: 25782020

Group type: EXPERIMENTAL
Intervention: Pulse therapy with methylprednisolone (500 mg daily intravenous for 3 days, followed by 1 mg/kg oral prednisolone for 11 days)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional oral prednisolone therapy (1 mg/kg oral prednisolone for 14 days)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups (pulse therapy and traditional therapy)
Number of subjects: 67
Study: 26677666

Group type: EXPERIMENTAL
Intervention: Qingre Yangyin Recipe (QRYYR), one dose per day in two portions, once in the morning and once in the evening.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metformin 500 mg, twice per day for 3 consecutive months.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined group (QRYYR and Metformin for the first month, then QRYYR for two months).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chinese herbs group (QRYYR).
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine group (Metformin).
Number of subjects: 90
Study: 23921769

Group type: EXPERIMENTAL
Intervention: ANS training on approximate addition and subtraction of arrays of dots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANS training
Number of subjects: 0
Study: 20206783

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 18
Study: 17968028

Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 mg/day to 80 mg/day (n = 271)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (n = 139)
Number of subjects: 410
Study: 15722000

Group type: EXPERIMENTAL
Intervention: Functional Cognitive Behavioral Therapy (fCBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 30
Study: 12706357

Group type: EXPERIMENTAL
Intervention: 5 mg tamoxifen (n=16)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 10 mg tamoxifen (n=14)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 20 mg tamoxifen (n=15)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 56
Study: 11049785

Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (2 g/day) combined with Saccharomyces boulardii (1 g/day for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose vancomycin (2 g/day) combined with placebo
Number of subjects: 0
Study: 8781465

Group type: EXPERIMENTAL
Intervention: Low plasma vitamin E level (lowest quartile)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked daily
Number of subjects: 410
Study: 1535400

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine with 3.0 ng/kg/min Ang II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Felodipine after placebo pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Felodipine after ramipril pretreatment
Number of subjects: 0
Study: 6494835

Group type: EXPERIMENTAL
Intervention: Autotraction
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual traction
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 49
Study: 30883058

Group type: EXPERIMENTAL
Intervention: TAVR with transfemoral placement of a balloon-expandable valve
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1000
Study: 29037578

Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine at 10 mcg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine at 6 mcg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, 1 mcg, and 3 mcg recipients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine (all doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V vaccine
Number of subjects: 60
Study: 24756324

Group type: EXPERIMENTAL
Intervention: Diode 808-nm laser-assisted treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 10
Study: 24961183

Group type: EXPERIMENTAL
Intervention: MG + MT
Number of subjects: 16

Group type: COMPARATOR
Intervention: MT
Number of subjects: 16
Study: 22085729

Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle (ASB) reconstruction
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle (ADB) reconstruction
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional single-bundle (CSB) reconstruction
Number of subjects: 320
Study: 19547802

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (200,000 IU)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (0 IU)
Number of subjects: 85
Study: 17923542

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with alpha‐l‐iduronidase (Aldurazyme)
Number of subjects: 8
Study: 15200537

Group type: EXPERIMENTAL
Intervention: Ultrasound visualisation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 40
Study: 16027532

Group type: EXPERIMENTAL
Intervention: Home Telemedicine Units (HTUs) installation and training by registered nurses (RNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technology-related problems during installation
Number of subjects: 0
Study: 10327509

Group type: EXPERIMENTAL
Intervention: deamino‐8‐D‐arginin vasopressin (0.3 microgram/kg body weight; maximum, 20 micrograms)
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: deamino‐8‐D‐arginin vasopressin
Number of subjects: 35
Study: 8723394

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17
Study: 1718119

Group type: EXPERIMENTAL
Intervention: Substance P (dose of 10(-9) - 10(-11) mol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Substance P (dose of 10(-10) mol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mustard oil (two concentrations)
Number of subjects: 40
Study: 7183186

Group type: EXPERIMENTAL
Intervention: Nicotine administration/cigarette smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 0
Study: 30982631

Group type: EXPERIMENTAL
Intervention: Clinical assessment group
Number of subjects: 285

Group type: COMPARATOR
Intervention: Procalcitonin-guided care group
Number of subjects: 285
Study: 28970180

Group type: EXPERIMENTAL
Intervention: Low-cost model
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cadaver
Number of subjects: 14
Study: 27025001

Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 186
Study: 25457418

Group type: EXPERIMENTAL
Intervention: SAQ training
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (straight-line sprint training)
Number of subjects: 132
Study: 23229960

Group type: EXPERIMENTAL
Intervention: Continuing Professional Development (CPD) workshops
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Continuing Pharmacy Education (CPE)
Number of subjects: 100
Study: 20627197

Group type: EXPERIMENTAL
Intervention: Stannous chloride-containing fluoride solution (800 ppm Sn(II), 500 ppm F, pH 4.5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sodium fluoride solution (500 ppm F, pH 4.5)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 120
Study: 17717202

Group type: EXPERIMENTAL
Intervention: GW274150 (90 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15785093

Group type: EXPERIMENTAL
Intervention: IFN-alpha (6 MIU intramuscularly daily for 2 weeks, then three times a week for 14 weeks, and finally twice a week for 88 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 11899189

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.5 minimum alveolar concentration) during the first 10 minutes of cardiopulmonary bypass (CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sevoflurane-free CPB)
Number of subjects: 20
Study: 10446040

Group type: EXPERIMENTAL
Intervention: Self-help intervention (n = 288) including a self-help booklet, a smoking and reproductive health information card, and three telephone counseling calls.
Number of subjects: 580

Group type: COMPARATOR
Intervention: Usual care (n = 292)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Self-help intervention (n = 288) among women with an abnormal Pap test result.
Number of subjects: 580

Group type: COMPARATOR
Intervention: Usual care (n = 292) among women with an abnormal Pap test result.
Number of subjects: 580
Study: 7595818

Group type: EXPERIMENTAL
Intervention: Child behavioral information
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Parental role information
Number of subjects: 108
Study: 31561351

Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsy (Fbx)
Number of subjects: 234
Study: 28841064

Group type: EXPERIMENTAL
Intervention: Hernia Repair Education Intervention (HREI)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study: 25460030

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) sublingually combined with PDE5 inhibitor sildenafil (50 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) sublingually combined with serotonin (5-HT)1A receptor agonist buspirone (10 mg)
Number of subjects: 21
Study: 22903517

Group type: EXPERIMENTAL
Intervention: Luminous biofeedback (LB group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acoustic biofeedback (AB group)
Number of subjects: 30
Study: 21940420

Group type: EXPERIMENTAL
Intervention: Adjuvant given 2 days after vaccine (group T5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent with vaccine (group T4)
Number of subjects: 70
Study: 18040163

Group type: EXPERIMENTAL
Intervention: HIV incidence among men
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: HIV incidence among women
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Sexual behaviour change
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: HIV prevention strategies effectiveness
Number of subjects: 3881
Study: 16109160

Group type: EXPERIMENTAL
Intervention: Five pound voucher redeemable at many high street stores
Number of subjects: 722

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 722
Study: 12031745

Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: alfentanil-propofol
Number of subjects: 40
Study: 10625102

Group type: EXPERIMENTAL
Intervention: 2 g of amoxicillin orally daily for 5 days postoperatively, starting at the completion of surgery
Number of subjects: 141

Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 141
Study: 8530624

Group type: EXPERIMENTAL
Intervention: 5 mg rhIGF-I, sc, twice daily
Number of subjects: 16
Study: 1673976

Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg, daily for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo, identical to astemizole, daily for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7102709

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acyclovir and dilute steroid drops
Number of subjects: 60
Study: 30025502

Group type: EXPERIMENTAL
Intervention: Microfinance and health leadership intervention
Number of subjects: 0
Study: 29952619

Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 82

Group type: COMPARATOR
Intervention: BMI + RT
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 82
Study: 26430929

Group type: EXPERIMENTAL
Intervention: Synbiotic bread containing Lactobacillus sporogenes (1 × 10^8 CFU) and 0.07 g inulin per 1 g
Number of subjects: 81

Group type: COMPARATOR
Intervention: Probiotic bread containing Lactobacillus sporogenes (1 × 10^8 CFU)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 81
Study: 24186848

Group type: EXPERIMENTAL
Intervention: Intervention group received repeated individual and group counseling on healthy lifestyles and guided antihypertensive therapy based on home BP measurements.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group received standard care without the comprehensive intervention.
Number of subjects: 220
Study: 21530322

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty with varying humeral versions (0°, 10°, 20° retroversion) and implant thicknesses (‐3, 0, +3 mm from baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty
Number of subjects: 0
Study: 19403551

Group type: EXPERIMENTAL
Intervention: Self- and manual mobilization (1 hour twice a week for 8 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study: 17653649

Group type: EXPERIMENTAL
Intervention: Peppermint oil (0.64 ml) in a test meal (200 kcal per 200 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Test meal alone (control)
Number of subjects: 10
Study: 15621316

Group type: EXPERIMENTAL
Intervention: Instantaneous low back compression loads for men
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Instantaneous low back compression loads for women
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily cumulative load for males
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily cumulative load for females
Number of subjects: 10